Noninvasive Liver Testing HepQuant offers non-invasive, quantitative liver health tests (DuO) that inform decisions on invasive procedures and treatment monitoring, presenting opportunities to partner with hospitals, clinics, and specialty labs seeking alternatives to biopsy.

Clinical Outcome Focus DuO’s ability to predict outcomes like ascites, encephalopathy, and variceal bleeding aligns with value-based care initiatives, enabling sales conversations with hepatology departments and payer-focused discussions around reduced complication rates and improved management.

Raising Clinical Adoption Recent conference activity and multiple abstracts indicate ongoing evidence development; potential to collaborate with academic centers and key opinion leaders to expand clinical adoption and generate real-world data for broader reimbursement.

Market Positioning Target mid to large healthcare systems and specialty liver clinics where non-invasive liver function testing can streamline patient pathways, reduce invasive procedure scheduling, and differentiate services in competitive gastroenterology markets.

Growth Readiness Company revenue in the low-to-mid single digits with a growing clinical footprint suggests upsell opportunities to expand DuO utilization across liver programs, integrate with existing lab and EHR workflows, and pursue payer negotiations for coverage of the DuO test.